Gene editing is no longer a speculative bet on distant science. With FDA-approved CRISPR therapies generating revenue, a $45 billion market projected by 2034, and the first human trial of age reversal underway, the question for investors has shifted from "if" to "how" — and "where."
This guide covers every major way to gain exposure to gene editing and genomics: ETFs, thematic indexes, venture capital funds, publicly traded companies across four continents, and the longevity-specific investment vehicles emerging as a new asset class.
The Gene Editing Market in Numbers
Before choosing investment vehicles, understand the scale:
- Current market size (2025): ~$8-10 billion
- Projected market size (2034): ~$45 billion (CAGR 16-18%)
- FDA-approved gene therapies: 10+ (Casgevy, Zolgensma, Luxturna, Hemgenix, Lyfgenia, Elevidys, and others)
- Active clinical trials: 150+ involving gene editing or gene therapy globally
- Venture funding into longevity alone: $5.2 billion in 2024
The sector breaks into three investable themes: gene editing tools and therapeutics (CRISPR, base editing, prime editing), gene therapy delivery and manufacturing (AAV, LNP, lentiviral), and longevity/aging biology (epigenetic reprogramming, senolytics, NAD+).
Genomics & Gene Editing ETFs
ETFs offer the simplest exposure with built-in diversification. Here are the six most relevant funds:
ARK Genomic Revolution ETF (ARKG)
| Metric | Value |
|---|---|
| Issuer | ARK Invest (Cathie Wood) |
| Expense Ratio | 0.75% |
| AUM | ~$1.2 billion |
| Holdings | ~35 positions |
| Style | Actively managed |
| 1Y Return (2025) | +23.0% |
| Key Gene Editing Holdings | CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics, Twist Bioscience, 10x Genomics |
ARKG is the largest and most well-known genomics ETF. It is actively managed by Cathie Wood's team, which means it takes concentrated positions and can deviate significantly from indexes. The fund peaked near $9 billion in AUM during the 2021 biotech bubble and has not recovered that level, but it remains the dominant retail vehicle for genomics exposure.
Pros: Largest AUM, active stock selection, high conviction positions in gene editing pure-plays Cons: Highest expense ratio (0.75%), concentrated portfolio increases volatility, significant drawdown from 2021 highs
Global X Genomics & Biotechnology ETF (GNOM)
| Metric | Value |
|---|---|
| Issuer | Global X (Mirae Asset) |
| Expense Ratio | 0.50% |
| AUM | ~$47 million |
| Holdings | 47 stocks |
| Style | Passively managed |
| Tracks | Solactive Genomics Index |
| Key Holdings | CRISPR Therapeutics, Vertex Pharmaceuticals, Intellia, Beam, Illumina |
GNOM tracks the Solactive Genomics Index and offers broader, more rules-based exposure than ARKG. Its lower expense ratio and passive management appeal to investors who want systematic genomics exposure without active manager risk.
Pros: Lower cost, rules-based, broader diversification Cons: Small AUM ($47M — watch for liquidity), declining inflows
iShares Genomics Immunology and Healthcare ETF (IDNA)
| Metric | Value |
|---|---|
| Issuer | BlackRock |
| Expense Ratio | 0.47% |
| AUM | ~$143 million |
| Holdings | Broad genomics + immunology |
| Style | Passively managed |
| Exchange | NYSE Arca |
IDNA is BlackRock's entry in the genomics space, covering a broader mandate that includes immunology and healthcare alongside genomics. It's the best option for investors who want genomics exposure within a larger healthcare context, backed by BlackRock's institutional infrastructure.
Pros: BlackRock brand, lowest expense ratio, broader healthcare mix reduces volatility Cons: Less pure-play gene editing exposure, diluted by broader healthcare holdings
Franklin Genomic Advancements ETF (HELX)
| Metric | Value |
|---|---|
| Issuer | Franklin Templeton |
| Expense Ratio | 0.50% |
| AUM | ~$20 million |
| Holdings | 65 securities |
| Style | Actively managed |
| Top Holdings | Thermo Fisher Scientific, Danaher, Repligen, Vertex |
HELX takes a broader approach, including life sciences tools companies (Thermo Fisher, Danaher) alongside therapeutics. This "picks and shovels" strategy means less direct gene editing exposure but potentially more stable returns.
Pros: Includes profitable tools companies, actively managed, diversified Cons: Very small AUM, less direct gene editing exposure
Other Notable ETFs with Genomics Overlap
| ETF | Ticker | Focus | 2025 Return | Expense Ratio |
|---|---|---|---|---|
| SPDR S&P Biotech | XBI | Equal-weight biotech | +35.9% | 0.35% |
| Virtus LifeSci Clinical Trials | BBC | Clinical-stage biotech | +63.7% | 0.79% |
| ALPS Medical Breakthroughs | SBIO | Mid/small-cap clinical biotech | +55.1% | 0.50% |
| Tema Oncology | CANC | Cancer therapeutics | +42.9% | 0.75% |
| WisdomTree BioRevolution | WDNA | Broad bio-revolution | N/A | 0.45% |
XBI deserves special mention: while not genomics-specific, its equal-weight methodology gives higher exposure to small-cap gene editing companies than market-cap-weighted biotech ETFs. Many gene editing pure-plays (Beam, Intellia, Caribou) are among its holdings.
ETF Comparison: Which to Choose?
| If you want... | Choose | Why |
|---|---|---|
| Maximum gene editing exposure | ARKG | Highest concentration in CRISPR/base editing companies |
| Low-cost passive genomics | GNOM | Tracks Solactive Genomics Index at 0.50% |
| Stable genomics + healthcare | IDNA | BlackRock, lowest cost, broader healthcare buffer |
| Picks-and-shovels approach | HELX | Tools companies (Thermo Fisher, Illumina) alongside therapeutics |
| Broad biotech with gene editing tilt | XBI | Equal-weight gives outsize exposure to small-cap gene editors |
Thematic Indexes
Several indexes track the genomics and gene editing sector, providing benchmarks and underlying frameworks for ETFs:
Solactive Genomics Index
- Provider: Solactive (Frankfurt)
- Tracked by: GNOM ETF
- Methodology: Companies active in gene editing, genomic sequencing, genetic medicine, computational genomics, and genetic diagnostics
- Use case: Benchmark for passive genomics investing
S&P Kensho Genetic Engineering Index (KDNA)
- Provider: S&P Dow Jones Indices
- Methodology: Companies using biotechnology to alter genes in organisms — a subsector of the S&P Kensho New Economy Index Series
- Use case: Institutional benchmark for genetic engineering sector performance
Indxx Global Longevity Thematic Index
- Tracked by: Global X Aging Population ETF (AGNG, ~$76M AUM)
- Methodology: Companies positioned to benefit from aging demographics — healthcare, pharmaceuticals, senior living, longevity technology
- Use case: Broader aging economy exposure (not gene editing-specific)
Venture Capital: Where the Smart Money Goes
The most transformative gene editing and longevity companies are still private. Here's where institutional capital is flowing:
ARCH Venture Partners
- Latest fund: $3 billion (September 2024)
- Total portfolio: 279 companies, 50+ unicorns
- Gene editing investments: Beam Therapeutics, Sana Biotechnology, delivery platform companies
- Longevity investments: Altos Labs
- Recent exits: Generate Biomedicines (NASDAQ, $2B market cap), Maze Therapeutics (NASDAQ)
ARCH is arguably the most important venture firm in gene editing. Their early bet on Beam Therapeutics before base editing was widely understood exemplifies their deep scientific conviction.
Flagship Pioneering
- AUM: $14 billion
- Portfolio: 85+ companies, 25 public exits
- Gene therapy portfolio: Tessera Therapeutics (Gene Writing, $582M raised), Ring Therapeutics (anellovirus delivery), Moderna (mRNA)
- Style: De novo company creation — they build companies from scratch around scientific breakthroughs rather than funding external founders
a16z Bio + Health
- Allocation: $700 million to Bio + Health from $15B across five funds
- Key move: Partnered with Eli Lilly to launch a $500M Biotech Ecosystem Venture Fund for early-stage biotechs
- Focus: Novel modality platforms, emerging health technologies, and computational biology
Khosla Ventures
- Portfolio: 710 companies, 59 new investments in last 12 months
- Longevity investments: NewLimit, Rubedo Life Sciences, Rejuvenation Technologies, Circulate Health
- Position: Arguably the most prolific dedicated longevity investor in Silicon Valley
Dedicated Longevity Funds
| Fund | Size | Focus | Notable |
|---|---|---|---|
| Hevolution Foundation | ~$1 billion | Healthspan science globally | Saudi-backed; chaired by Mehmood Khan (also Life Biosciences chairman) |
| Korify Capital | $100 million | Longevity and mental health | Basel, Switzerland; 15-20 companies across Europe, US, Israel |
| Longevity Vision Fund | Undisclosed | Early-stage longevity | Sergey Young; invested in 50+ longevity startups |
Top Private Longevity Companies (For Sophisticated Investors)
Pre-IPO markets (Forge Global, EquityZen) occasionally offer secondary market access to:
| Company | Valuation | Raised | Status |
|---|---|---|---|
| Altos Labs | $6.3B | $3B+ | Preclinical (Bezos-backed) |
| Cambrian Biopharma | $1.8B | $160M+ | 14 aging drug candidates |
| NewLimit | $1.6B | $175M+ | Series B (Armstrong-backed, human trials ~2028) |
| Retro Biosciences | Undisclosed | $180M | Sam Altman-backed, 3 aging pathways |
| Life Biosciences | Undisclosed | $175M | Phase 1 (first human epigenetic reprogramming trial) |
Publicly Traded Gene Editing Companies: The Global Map
Gene editing is not a US-only story. Here are the publicly traded companies by region:
United States
| Company | Ticker | Market Cap | Focus | Key Catalyst |
|---|---|---|---|---|
| CRISPR Therapeutics | CRSP | ~$4.5B | CRISPR-Cas9, Casgevy | Revenue ramp ($300M projected 2026) |
| Intellia Therapeutics | NTLA | ~$1.6B | In vivo CRISPR via LNPs | NTLA-2001 Phase 3 (ATTR) |
| Beam Therapeutics | BEAM | ~$2.6B | Base editing | Pfizer $300M + Lilly $200M deals |
| Editas Medicine | EDIT | ~$300M | CRISPR-Cas12a (rene-cel) | Phase 1/2 SCD data |
| Caribou Biosciences | CRBU | ~$185M | chRDNA CRISPR, allogeneic CAR-T | CB-010 Phase 1 lymphoma |
| Prime Medicine | PRME | ~$400M | Prime editing | Chronic granulomatous disease |
| Sangamo Therapeutics | SGMO | ~$150M | ZFN, gene regulation | Fabry disease Phase 3 |
| Wave Life Sciences | WVE | ~$1.2B | RNA editing (stereopure oligonucleotides) | Duchenne Phase 2 |
Europe
| Company | Ticker | Exchange | Country | Market Cap | Focus |
|---|---|---|---|---|---|
| BioNTech | BNTX | NASDAQ | Germany | ~$22B | mRNA oncology, 15 Phase 3 trials by end 2026 |
| Cellectis | CLLS | NASDAQ/Euronext | France | ~$450M | TALEN gene editing, allogeneic CAR-T; AstraZeneca collaboration |
| MeiraGTx | MGTX | NASDAQ | UK | ~$623M | AAV gene therapy; ocular, Parkinson's; J&J collaboration |
| CRISPR Therapeutics | CRSP | NASDAQ | Switzerland | ~$4.5B | (HQ Zug, listed in US) |
| Cimeio Therapeutics | Private | -- | Switzerland | Undisclosed | Selective gene therapy conditioning |
Asia-Pacific
| Company | Ticker | Exchange | Country | Market Cap | Focus |
|---|---|---|---|---|---|
| ToolGen | 199800 | KOSDAQ | South Korea | ~$184M | CRISPR-Cas9 IP and tools for eukaryotic cells |
| Modalis Therapeutics | 4883 | TSE | Japan | ~$26M | Non-cutting CRISPR (CRISPR-GNDM) epigenetic gene modulation |
| HuidaGene Therapeutics | Private | -- | China | Undisclosed | CRISPR/Cas13 RNA editing; first FDA-cleared Cas13 therapy (HG202 for nAMD) |
| EdiGene | Private | -- | China | ~$67M+ raised | CRISPR + LEAPER RNA editing; beta-thalassemia, CAR-T |
| Benitec Biopharma | BLT | ASX | Australia | Small-cap | Gene silencing (ddRNAi); ASX's only gene therapy company |
Key Global Observations
- The US dominates with 8+ publicly traded pure-play gene editing companies and the largest market caps
- Europe has pockets of excellence: Cellectis (France) owns key TALEN IP, BioNTech (Germany) is applying mRNA to oncology at massive scale
- China is the wildcard: HuidaGene's FDA clearance for the first-ever CRISPR/Cas13 RNA editing therapy signals China can compete at the cutting edge, but private status limits investor access
- South Korea and Japan have single notable entries but with significant IP (ToolGen holds foundational CRISPR patents)
- India lacks pure-play listings but the government's "Biopharma Shakti" program (10,000 crore rupees over 5 years) signals coming investment in gene therapy infrastructure
Investment Strategies by Risk Profile
Conservative: ETF + Large-Cap Biotech
- Core position in IDNA or XBI for diversified exposure
- Satellite positions in Vertex Pharmaceuticals (VRTX, Casgevy revenue partner) and Regeneron (REGN, gene therapy pipeline)
- Expense budget: 0.35-0.47% annually
Moderate: Targeted Gene Editing Pure-Plays
- ARKG as core genomics allocation
- Direct positions in clinical-stage leaders: CRSP (revenue-generating), NTLA (Phase 3 catalyst), BEAM (pharma partnerships de-risk)
- BioNTech (BNTX) for mRNA crossover exposure
- Monitor Cellectis (CLLS) for AstraZeneca deal value
Aggressive: Pre-Revenue + Pre-IPO
- Small-cap pure-plays: Caribou (CRBU), Prime Medicine (PRME), Editas (EDIT)
- Pre-IPO access via Forge Global/EquityZen: Altos Labs, NewLimit, Cambrian Biopharma
- Direct longevity exposure: Life Biosciences (Phase 1 data catalyst late 2026)
- High risk/high reward: ToolGen (KOSDAQ, CRISPR patent portfolio)
Key Catalysts to Watch (2026-2027)
| Catalyst | Company | Timeline | Potential Impact |
|---|---|---|---|
| Casgevy revenue ramp | CRISPR Therapeutics | 2026 ongoing | Proves gene editing commercial viability |
| NTLA-2001 Phase 3 data | Intellia | Late 2026 | First in vivo CRISPR pivotal results |
| ER-100 Phase 1 readout | Life Biosciences | Late 2026/early 2027 | First human epigenetic reprogramming data |
| BEAM-101 Phase 1/2 data | Beam Therapeutics | 2026 | Base editing for SCD |
| HG202 clinical progress | HuidaGene | 2026 | First Cas13 RNA editing therapy |
| Altos Labs IND filing | Altos Labs | 2026-2027 | Validates $3B+ investment thesis |
| NewLimit human trials | NewLimit | ~2028 | Liver epigenetic reprogramming |
Risk Factors for Gene Editing Investors
Regulatory risk: Each new gene editing modality faces novel regulatory pathways. The FDA has no precedent for approving age-reversal therapies.
Reimbursement risk: Gene therapies cost $850K-$3.5M per treatment. Payer pushback could limit commercial adoption even for approved therapies.
Technical risk: Many gene editing approaches that work in mice fail in humans. The 2024 Verve Therapeutics safety signal (patient death in VERVE-101 trial) demonstrated that permanent cardiovascular gene edits carry real risk.
Competition risk: The field is crowded. CRISPR, base editing, prime editing, RNA editing, and epigenetic editing are all competing for the same disease targets.
Patent risk: CRISPR patent ownership remains contested in some jurisdictions. ToolGen, Broad Institute, UC Berkeley, and others hold overlapping claims.
China risk: Chinese gene editing companies (EdiGene, HuidaGene) may face geopolitical barriers to US market access.
The Bottom Line
Gene editing is transitioning from a research-stage sector to a revenue-generating industry. Casgevy is treating patients. Intellia is in Phase 3. Life Biosciences is testing age reversal in humans. The investment landscape has matured accordingly — from speculative biotech bets to a structured ecosystem of ETFs, thematic indexes, venture funds, and publicly traded companies spanning four continents.
For most investors, a combination of a genomics ETF (ARKG for conviction, IDNA for stability) plus selective positions in clinical-stage leaders (CRSP, NTLA, BEAM) provides the best risk-adjusted exposure. For those with higher risk tolerance and longer time horizons, the longevity space — anchored by Altos Labs, Life Biosciences, and NewLimit — represents a potentially transformative bet on the future of medicine.
Sources & Further Reading
- ARK Invest — ARKG Fund Page
- Solactive Genomics Index
- S&P Kensho Genetic Engineering Index
- Motley Fool — Top ETFs Tracking CRISPR Gene Editing
- STAT News — ARCH Venture Raises $3B
- Fierce Biotech — Korify $100M Longevity Fund
- Grand View Research. "Gene Editing Market Size, Share & Trends Analysis Report." (2025).
Last updated: March 2026. This article is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.
